Cargando…

Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center

Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective s...

Descripción completa

Detalles Bibliográficos
Autores principales: Brescini, Lucia, Della Martera, Filippo, Morroni, Gianluca, Mazzanti, Sara, Di Pietrantonio, Maria, Mantini, Paolo, Candelaresi, Bianca, Pallotta, Francesco, Olivieri, Silvia, Iencinella, Valentina, Castelletti, Sefora, Cocci, Emanuele, Polo, Rosaria G., Veccia, Salvatore, Cirioni, Oscar, Tavio, Marcello, Giacometti, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468778/
https://www.ncbi.nlm.nih.gov/pubmed/34572711
http://dx.doi.org/10.3390/antibiotics10091129
_version_ 1784573758641537024
author Brescini, Lucia
Della Martera, Filippo
Morroni, Gianluca
Mazzanti, Sara
Di Pietrantonio, Maria
Mantini, Paolo
Candelaresi, Bianca
Pallotta, Francesco
Olivieri, Silvia
Iencinella, Valentina
Castelletti, Sefora
Cocci, Emanuele
Polo, Rosaria G.
Veccia, Salvatore
Cirioni, Oscar
Tavio, Marcello
Giacometti, Andrea
author_facet Brescini, Lucia
Della Martera, Filippo
Morroni, Gianluca
Mazzanti, Sara
Di Pietrantonio, Maria
Mantini, Paolo
Candelaresi, Bianca
Pallotta, Francesco
Olivieri, Silvia
Iencinella, Valentina
Castelletti, Sefora
Cocci, Emanuele
Polo, Rosaria G.
Veccia, Salvatore
Cirioni, Oscar
Tavio, Marcello
Giacometti, Andrea
author_sort Brescini, Lucia
collection PubMed
description Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective study of the use of dalbavancin in 55 patients at the Azienda Ospedaliera Ospedali Riuniti Umberto I (Ancona, Italy) from February 2017 to May 2020 and compared “on label” and “off label” use of dalbavancin in ABSSSI and non-ABSSSI. Results: A total of 55 patients were included in the study. The median age was 61 years; 51% had ABSSSI; 24% had prosthetic joint infections, and 14% had osteomyelitis. A total of 53% received a single 1500 mg infusion of dalbavancin, and 18% received a second dose 14 days later; 24% of patients received further doses at 14-day intervals. In 91% of cases, patients achieved clinical objectives with dalbavancin: 96% of patients with ABSSSI and 69% of those with prosthetic joint infections. Conclusions: Dalbavancin was shown to have an excellent tolerability profile and to be a highly successful therapeutic approach even in those cases treated “off-label”.
format Online
Article
Text
id pubmed-8468778
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84687782021-09-27 Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center Brescini, Lucia Della Martera, Filippo Morroni, Gianluca Mazzanti, Sara Di Pietrantonio, Maria Mantini, Paolo Candelaresi, Bianca Pallotta, Francesco Olivieri, Silvia Iencinella, Valentina Castelletti, Sefora Cocci, Emanuele Polo, Rosaria G. Veccia, Salvatore Cirioni, Oscar Tavio, Marcello Giacometti, Andrea Antibiotics (Basel) Article Dalbavancin is a lipoglycopeptide approved for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The aim of the study was to evaluate the efficacy and safety in all patients who received at least one administration of dalbavancin. Methods: We carried out a retrospective study of the use of dalbavancin in 55 patients at the Azienda Ospedaliera Ospedali Riuniti Umberto I (Ancona, Italy) from February 2017 to May 2020 and compared “on label” and “off label” use of dalbavancin in ABSSSI and non-ABSSSI. Results: A total of 55 patients were included in the study. The median age was 61 years; 51% had ABSSSI; 24% had prosthetic joint infections, and 14% had osteomyelitis. A total of 53% received a single 1500 mg infusion of dalbavancin, and 18% received a second dose 14 days later; 24% of patients received further doses at 14-day intervals. In 91% of cases, patients achieved clinical objectives with dalbavancin: 96% of patients with ABSSSI and 69% of those with prosthetic joint infections. Conclusions: Dalbavancin was shown to have an excellent tolerability profile and to be a highly successful therapeutic approach even in those cases treated “off-label”. MDPI 2021-09-19 /pmc/articles/PMC8468778/ /pubmed/34572711 http://dx.doi.org/10.3390/antibiotics10091129 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Brescini, Lucia
Della Martera, Filippo
Morroni, Gianluca
Mazzanti, Sara
Di Pietrantonio, Maria
Mantini, Paolo
Candelaresi, Bianca
Pallotta, Francesco
Olivieri, Silvia
Iencinella, Valentina
Castelletti, Sefora
Cocci, Emanuele
Polo, Rosaria G.
Veccia, Salvatore
Cirioni, Oscar
Tavio, Marcello
Giacometti, Andrea
Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
title Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
title_full Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
title_fullStr Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
title_full_unstemmed Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
title_short Use of Dalbavancin in Skin, Bone and Joint Infections: A Real-Life Experience in an Italian Center
title_sort use of dalbavancin in skin, bone and joint infections: a real-life experience in an italian center
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8468778/
https://www.ncbi.nlm.nih.gov/pubmed/34572711
http://dx.doi.org/10.3390/antibiotics10091129
work_keys_str_mv AT brescinilucia useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT dellamarterafilippo useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT morronigianluca useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT mazzantisara useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT dipietrantoniomaria useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT mantinipaolo useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT candelaresibianca useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT pallottafrancesco useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT olivierisilvia useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT iencinellavalentina useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT castellettisefora useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT cocciemanuele useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT polorosariag useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT vecciasalvatore useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT cirionioscar useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT taviomarcello useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter
AT giacomettiandrea useofdalbavancininskinboneandjointinfectionsareallifeexperienceinanitaliancenter